SEC Form 4 · accession 0000899243-16-025047
Wave Life Sciences, Inc. · WVE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael A. Panzara
Officer — Franchise Lead, Neurology
Period of report
Jul 11, 2016
Accepted (ET)
Jul 13, 2016 · 4:14 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001631574
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF2 | Jul 11, 2016 | A | 22,750 | $0.00 | A | 22,750 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Share Option (right to buy)F1 | $21.69 | Jul 11, 2016 | A | 150,000 | A | — | Jul 11, 2026 | Ordinary Shares | 150,000 | 150,000 | D |
Explanation of responses
- F1The option vests as to 25% of the shares on July 11, 2017 and vests as to an additional 2.0833% of the shares monthly thereafter until July 11, 2020.
- F2Consists of restricted stock units (RSUs). The RSUs vest as to 100% of the shares on July 11, 2017.